李强主持召开国务院常务会议 听取国家水网建设情况汇报，部署复制推广跨境贸易便利化专项行动政策措施，审议通过《供水条例（草案）》和《中华人民共和国药品管理法实施条例（修订草案）》

Group 1: National Water Network Construction - The meeting highlighted the progress in the construction of the national water network, emphasizing its role in optimizing water resource allocation, enhancing flood prevention and disaster reduction capabilities, and ensuring national water security [1] - The construction of the national water network is seen as a strategic measure with multiple benefits, including transportation, ecological protection, and tourism, serving as a key driver for expanding domestic demand [1] - The meeting called for innovative investment and financing mechanisms, encouraging state-owned enterprises to increase investment and attract private capital for multi-channel funding of construction projects [1] Group 2: Cross-Border Trade Facilitation - Cross-border trade facilitation is identified as a crucial element in creating a first-class business environment, with a focus on enhancing efficient logistics and multi-modal transport coordination [2] - The meeting emphasized the development of new business models such as green trade and cross-border e-commerce, along with optimizing the regulation of special goods [2] - There is a push for improving smart regulatory services and strengthening quality control of import and export goods to ensure efficient and effective trade management [2] Group 3: Drug Management Regulations - The meeting underscored the importance of timely revisions to drug management laws and regulations in response to changing circumstances, which is vital for ensuring public safety in medication and promoting a healthy pharmaceutical industry [3] - There is a focus on improving drug research and registration systems, expediting the review and approval of breakthrough therapies to stimulate industry innovation [3] - The meeting called for maintaining a stringent regulatory environment, enhancing quality supervision across the entire drug supply chain, and cracking down on illegal activities in the pharmaceutical sector [3]